Builds on company’s more than $3b U.S. investment since 2018 which created thousands of new jobs across 44 states
KING OF PRUSSIA, PA, USA – November 18, 2025 — Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced plans to expand its U.S. presence over the next five years, resulting in approximately US$1.5b in U.S. capital investments. These investments will generate hundreds of high-quality American jobs, strengthen U.S. manufacturing capabilities of plasma-derived therapies (PDTs), and help secure the U.S. medicine supply chain. This reflects CSL’s commitment to meet the growing clinical need for immunoglobulin (Ig) over the long term.
“The U.S. is the world’s leading source for plasma, the main component of plasma derived therapies,” said Paul McKenzie, Chief Executive Officer and Managing Director, CSL. “These important medicines are often the most effective or only therapies available for many rare or serious diseases. By expanding our onshore production capacity in the U.S., we are deepening our commitment to patient care, creating high-quality jobs and driving innovation in the U.S.”
These planned investments are subject to approval by CSL’s Board of Directors.
Since 2018, CSL has invested over $3 billion into its U.S. operations, creating more than 6,500 new American jobs and bringing our total U.S. headcount to nearly 19,000, representing about 65% of CSL’s workforce.
CSL provides meaningful career opportunities for Americans nationwide from roles in manufacturing to scientific innovation. CSL’s plasma centers serve as an entry point into the healthcare sector, launching new careers and employing thousands of individuals across the country.
About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL - including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor - provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita For more information about CSL, visit CSL.com.
Media Contacts
Ken Inchausti, CSL Behring
Mobile: +1 267.524.5750
Email: ken.inchausti@cslbehring.com
Tom Hushen, CSL
Mobile: +1 267.769.6728
Email: thomas.hushen@cslbehring.com